Loading data for CABA — first visit, this takes a few seconds.

Alerta

Cabaletta Bio Inc. (CABA)

NasdaqGS: CABA · Precio en tiempo real · USD

2.91

+0.02 (0.69%)

Al cierre: Aug 19, 2026, 8:00 PM

3.12

+0.65%

Premercado: 4:02 AM

0.69% (1D)

No hay datos disponibles

Precio de compra	2.11
Capitalización de mercado	525.59M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-181.32M
Beta	3.25
EPS (TTM)	-1.47
Ratio PER (TTM)	n/a
Adelante PE	-2.1
P/B (TTM)	2.47
P/S (TTM)	n/a
Earnings Date	Nov 16, 2026

Precio de venta	3.62
Volumen	6,965,483
Volumen medio (20D)	4,480,558
Abierto	2.86
Anterior Cerrar	2.89
Rango del día	2.82 - 2.96
Rango de 52 semanas	1.40 - 4.23
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenil...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Oct 25, 2019

Empleados 154

Bolsa de Valores NasdaqGS

Símbolo bursátil CABA

Sitio web https://www.cabalettabio.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Cabaletta Bio fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -167.86M, un aumento de 44.87%.

Estados financieros

Sorpresa de resultados

Cabaletta Bio ha publicado sus resultados trimestrales en Aug 13, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.34 falla las estimaciones por 0.00, con 53.42% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Cabaletta Bio Inc. publique sus resultados el Nov 16, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 mes hace · 24/7 Wall St.

Kyverna Therapeutics Sinks 13%: Here’s Why

A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity...

2 meses hace · Insider Monkey

How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup

Cabaletta Bio, Inc. (NASDAQ:CABA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s 2026 story is focused on rese-cel, an experimental cell therapy being developed for ...

2 meses hace · Exec Edge

FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases

By Karen Roman Imviva Biotech said the FDA cleared its Investigational New Drug application for CTA313, a dual-targeted CAR-T therapy for the treatment of B-cell-mediated autoimmune diseases. Phase 1b...

2 meses hace · Insider Monkey

Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases

Cabaletta Bio Inc. (NASDAQ:CABA) is one of the top penny stocks to buy in investors’ stock portfolio. On May 14, Cabaletta Bio Inc. (NASDAQ:CABA) delivered positive clinical and translational data fro...

3 meses hace · Zacks

Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?

Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

Página 1 de 2

Cabaletta Bio Inc. (CABA)